← Back to Search

Immunotoxin

Denileukin Diftitox for Lymphoma

Phase 2

Waitlist Available

Research Sponsored by Pharmatech Oncology

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well denileukin diftitox works in treating patients with non-Hodgkin's lymphoma.

Who is the study for?

This trial is for adults with B-cell non-Hodgkin's lymphoma, including various subtypes and stages. Participants must have previously received or be ineligible for monoclonal antibody therapy, have measurable disease, and adequate organ function. They cannot join if they're pregnant/nursing, HIV positive, have serious illnesses that could interfere with the study, known hypersensitivity to the drug components, or other malignancies within 5 years (with some exceptions).Check my eligibility

What is being tested?

The trial is testing denileukin diftitox's effectiveness in treating non-Hodgkin's lymphoma. It’s a phase II study which means it focuses on how well the treatment works and further evaluates its safety.See study design

What are the potential side effects?

Denileukin diftitox may cause allergic reactions due to its components like diphtheria toxin or interleukin-2. Other potential side effects include fatigue, nausea, fever, rash or infections due to immune system impact.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Pharmatech OncologyLead Sponsor

4 Previous Clinical Trials

180 Total Patients Enrolled

2 Trials studying Leukemia

180 Patients Enrolled for Leukemia

Debby HenkensStudy ChairPharmatech Oncology

Media Library

Denileukin Diftitox (Immunotoxin) Clinical Trial Eligibility Overview. Trial Name: NCT00026429 — Phase 2

Leukemia Clinical Trial 2023: Denileukin Diftitox Highlights & Side Effects. Trial Name: NCT00026429 — Phase 2

Denileukin Diftitox (Immunotoxin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00026429 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this medication been given the okay by the FDA?

"While Phase 2 trials don't have the same level of efficacy data as Phase 3, this treatment still received a score of 2 for safety."

Answered by AI

How many different medical clinics are conducting this study?

"Presently, this research is being conducted at 6 different test facilities. The locations are situated in Rancho Mirage, Pomona and St. Charles as well as other areas. If you enroll, try to select the location that is closest to your home to reduce travel time commitments."

Answered by AI

Are new participants being enrolled in this experiment at present?

"No, this particular clinical trial is not looking for new patients at the moment. This information can be found on clinicaltrials.gov; the original posting was on January 1st, 2001 and there was a most recent update on December 17th, 2013. There are over two thousand other trials that are actively recruiting patients right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

2001. "Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00026429.

All > Childhood Leukemia > Lymphoma